Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.
about
Ontogeny of midazolam glucuronidation in preterm infants.Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus.Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells.Pharmacokinetics of dideoxyinosine in neonatal pigtailed macaques.Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.Toxicokinetics in infants and children in relation to the ADI and TDI.Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.Pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in the neonatal macaque (Macaca nemestrina).Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology.Paediatric pharmacokinetics: key considerations.Maternal adherence to the zidovudine regimen for HIV-exposed infants to prevent HIV infection: a preliminary study.Pharmacotherapy of pediatric HIV infectionGuidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine.Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected childrenFactors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and AdultsPharmacokinetic optimization of antiretroviral therapy in children and adolescents.Prediction of drug clearance in children 3 months and younger: an allometric approach.Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Theoretical pharmacokinetic drug alterations in pediatric celiac disease.Challenges Associated with Route of Administration in Neonatal Drug Delivery.Pharmacokinetic considerations in the use of antivirals in neonates.Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours.Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000).Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection.Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations.British HIV Association guidelines for the management of HIV infection in pregnant women 2012
P2860
Q33587843-4FBDF775-2C87-41E8-A886-956BD47FFF21Q33692439-90AB8C5A-5FF3-4156-9BD5-AB7FF07B859FQ33747461-B51621D0-3075-4C55-B19D-7A38C275F941Q33752888-DD4250F3-D457-4C03-8283-283D390A4B3AQ33976456-84502310-2C92-4A2A-8F4E-2702E8973AB5Q34469520-FDC7A6B5-8F62-475F-93B3-049FC2D025E9Q35110966-6444D1CA-8EEA-4910-9036-AA921F083F62Q35121223-D3610A97-C11C-427D-B1BA-94397649BC10Q35129433-148D16AE-222B-432B-84D6-DF9104683FD7Q35135940-6E1AE3E4-2F3B-43FD-A2CB-498AC0E2095BQ36031465-1D754577-33DB-44A7-8AA3-10ADDAB15AD5Q36301325-C62A0F21-F4FF-40DA-90D2-075ACE9E6110Q36627208-C4D4E6EF-BE95-4AE4-A3DF-E8936E1A2C74Q36702365-5992A133-E054-482C-9F66-FE1B5E41A2ABQ37115759-4B5CEB51-0178-48D6-8BA4-548142843670Q37263890-36D4368B-3356-4F27-81B6-565086BCCF52Q37378093-DCCC9251-E502-4936-ACA9-9E6E3F6CA98CQ37835819-5644BB2E-29D9-46AE-B4B5-8160781BA6A9Q37854677-E23367E0-36E4-46BA-85B7-ACC4A5CE5017Q38187348-BFC3F45B-8A30-43D2-BC92-6FC1A023E3F9Q38325427-4B4B3E48-4955-4CD5-AF68-B279BA2D2750Q38544086-CA3DBE39-4C8B-41C8-9086-1B6A0AE3245FQ38561363-96B4F730-6E3E-4107-8D21-350D782C9BE8Q38624965-EAC467DA-3A23-4E45-99BB-9C3178A32EC8Q39038877-E7B7EA1B-E3F7-4BF5-BAB4-B6941801D204Q43673455-6BA264A5-7D97-40D4-B49C-4B405A6F38C9Q43956302-51F2F5D5-39E8-4317-A17A-D01A2BBC30E1Q44343579-E4E6F4A0-7749-448F-A2C8-CCF7D7CB725AQ45753600-DEAF3AF7-2722-4ABC-AA8C-F9E83D42CC56Q45932455-D1EECFD4-8B4E-47C3-BC35-35B7119D8939Q57076282-A5C46E73-6A5A-4B50-B118-9BFD06B792FB
P2860
Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Phase I evaluation of zidovudi ...... human immunodeficiency virus.
@en
Phase I evaluation of zidovudi ...... human immunodeficiency virus.
@nl
type
label
Phase I evaluation of zidovudi ...... human immunodeficiency virus.
@en
Phase I evaluation of zidovudi ...... human immunodeficiency virus.
@nl
prefLabel
Phase I evaluation of zidovudi ...... human immunodeficiency virus.
@en
Phase I evaluation of zidovudi ...... human immunodeficiency virus.
@nl
P2093
P1476
Phase I evaluation of zidovudi ...... human immunodeficiency virus.
@en
P2093
Boucher FD
McKinney R Jr
Mirochnick M
P304
P356
10.1016/S0022-3476(05)83507-3
P407
P577
1993-01-01T00:00:00Z